Single-pore silica nanotherapeutic platform with pH-Responsive NO release for osteoporosis repair
Source abstract
Abstract
Osteoporosis is a systemic bone disease with progressive deterioration of the bone microarchitecture. A key trigger for Osteoporosis is oxidative stress damage caused by reactive oxygen species (ROS). Nitric oxide (NO) can prevent excessive production of ROS in the bone microenvironment by regulating the abnormal opening of the mitochondrial permeability transition pore (mPTP). NO, as a highly active molecule, also plays an important role in bone regeneration and bone remodeling. However, its short half-life and unstable release severely limit its clinical application. Herein, a pH-responsive NO-releasing nanotherapeutic platform (GSCe NPs) was developed. Single-pore silica nanoparticles (SPMSNs) were synthesized via calcination of nano selenium core, enabling high loading of the NO donor S-nitrosoglutathione (GSNO). GSNO@SPMSN was aminated and coated with Cerium dioxide (CeO 2 ) to form GSCe NPs. The CeO 2 outer layer protected NO from premature release, scavenged ROS to prevent NO oxidation, and catalyzed acid-triggered NO generation in the osteoporotic microenvironment. Released NO suppressed mPTP opening, inhibiting ROS accumulation and apoptosis. In dibutyl phthalate (DBP) and dexamethasone (DEX) treated mouse osteoblastic cell lines (MC3T3-E1), GSCe NPs enhanced proliferation, calcium deposition, and alkaline phosphatase (ALP) expression while restoring mitochondrial function. In ovariectomized mice, GSCe NPs improved bone microstructure, increased bone mass, and upregulated osteogenic markers including collagen type I (Col-I), bone morphogenetic protein 2 (BMP-2), runt-related transcription factor 2 (Runx2) and osteocalcin (OCN) with minimal toxicity. This pH-responsive NO-releasing platform offers a targeted strategy for osteoporosis repair by synergistically regulating ROS/NO/mitochondrial pathways.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Mesoporous Materials and Catalysis · Bone Tissue Engineering Materials · Aerogels and thermal insulation
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (67)
Show source-provided references
1. Metal-polyDNA nanoparticles reconstruct osteoporotic microenvironment for enhanced osteoporosis treatment10.1126/sciadv.adf3329 ↗
2. Oxidative stress and natural antioxidants in osteoporosis: novel preventive and therapeutic approaches10.3390/antiox12020373 ↗
3. Osteoporosis: now and the future10.1016/S0140-6736(10)62349-5 ↗
4. Skeletal remodeling in health and disease10.1038/nm1593 ↗
5. Age-related intrinsic changes in human bone-marrow-derived mesenchymal stem cells and their differentiation to osteoblasts10.1111/j.1474-9726.2008.00377.x ↗
6. Therapeutic approaches to bone diseases10.1126/science.289.5484.1508 ↗
7. Role of proton receptor OGR1 in bone response to metabolic acidosis?10.1016/j.kint.2015.12.031 ↗
8. Regulation of bone cell function by acid–base balance10.1079/PNS2003268 ↗
9. Breaking osteoclast-acid vicious cycle to rescue osteoporosis via an acid responsive organic framework-based neutralizing and gene editing platform10.1002/smll.202307595 ↗
10. Acid-base imbalance and the skeleton10.1007/s394-001-8351-5 ↗
11. Postmenopausal osteoporosis10.1038/nrdp.2016.69 ↗
12. Signal transduction by reactive oxygen species10.1083/jcb.201102095 ↗
13. Mesenchymal stem cells: cell fate decision to osteoblast or adipocyte and application in osteoporosis treatment10.3390/ijms19020360 ↗
14. Oxidative stress modulates osteoblastic differentiation of vascular and bone cells10.1016/S0891-5849(01)00610-4 ↗
15. In situ self-assembling micellar depots that can actively trap and passively release NO with long‐lasting activity to reverse osteoporosis10.1002/adma.201705605 ↗
16. Nitric oxide release: part II. Therapeutic applications10.1039/c2cs15273h ↗
17. Nitric oxide and bone10.1046/j.1365-2567.2001.01261.x ↗
18. Therapeutic effects of inorganic nitrate and nitrite in cardiovascular and metabolic diseases10.1111/joim.12441 ↗
19. Near-infrared light and upconversion nanoparticle defined nitric oxide-based osteoporosis targeting therapy10.1021/acsnano.1c04974 ↗
20. Advanced nitric oxide generating nanomedicine for therapeutic applications10.1021/acsnano.3c02303 ↗
21. The biphasic effects of nitric oxide in primary rat osteoblasts are cGMP dependent10.1006/bbrc.2000.3164 ↗
22. Nitric oxide donors: chemical activities and biological applications10.1021/cr000040l ↗
23. Nitric oxide (NO) protects against cellular damage by reactive oxygen species10.1016/0378-4274(95)03557-5 ↗
24. Near-infrared light-triggered nitric-oxide-enhanced photodynamic therapy and low-temperature photothermal therapy for biofilm elimination10.1021/acsnano.9b09871 ↗
25. Delivery of nitric oxide with a nanocarrier promotes tumour vessel normalization and potentiates anti-cancer therapies10.1038/s41565-019-0570-3 ↗
26. Nitric oxide‐releasing bioinspired scaffold for exquisite regeneration of osteoporotic bone via regulation of homeostasis10.1002/advs.202205336 ↗
27. Polymer-based nitric oxide therapies: recent insights for biomedical applications10.1002/adfm.201101707 ↗
28. Advanced nitric oxide donors: chemical structure of NO drugs, NO nanomedicines and biomedical applications10.1039/D0NR07484E ↗
29. Bactericidal efficacy of nitric oxide-releasing silica nanoparticles10.1021/nn700191f ↗
30. Progress and promise of nitric oxide‐releasing platforms10.1002/advs.201701043 ↗
31. Ceria nanoparticles as an unexpected catalyst to generate nitric oxide from s‐nitrosoglutathione10.1002/smll.202105762 ↗
32. Inflammatory microenvironment‐responsive nanomotors with NIR photothermal effect for deep inflammation elimination and infection inhibition10.1002/adfm.202416684 ↗
33. Bisphenol A and Di-n-butyl phthalate disrupt bone homeostasis bidirectionally via CD36-mediated BMSCs autophagy inhibition and exosome-promoted osteoclastogenesis
34. Ceria nanoparticles guard against glucocorticoid induced bone homeostasis imbalance through the promotion of osteogenesis and inhibition of osteoclastogenesis
35. High doses of dexamethasone induce endoplasmic reticulum stress-mediated apoptosis by promoting calcium ion influx-dependent CHOP expression in osteoblasts10.1007/s11033-021-06806-y ↗
36. PSMD14 stabilizes SLC7A11 to ameliorate glucocorticoid‐induced osteoporosis by suppressing osteocyte ferroptosis10.1002/advs.202414902 ↗
37. Tau is a receptor with low affinity for glucocorticoids and is required for glucocorticoid-induced bone loss10.1038/s41422-024-01016-0 ↗
38. Hong Zhou, Glucocorticoid-induced osteoporosis: mechanisms, management, and future perspectives10.1016/S2213-8587(13)70045-7 ↗
39. The key role of mitochondrial function in health and disease10.3390/antiox12040782 ↗
40. Mitochondrial heterogeneity in diseases
41. Mitochondrial transfer regulates cell fate through metabolic remodeling in osteoporosis10.1002/advs.202204871 ↗
42. Metformin attenuates H2O2-induced osteoblast apoptosis by regulating SIRT3 via the PI3K/AKT pathway10.3892/etm.2021.10751 ↗
43. The design of anionic surfactant-based amino-functionalized mesoporous silica nanoparticles and their application in transdermal drug delivery10.3390/pharmaceutics12111035 ↗
44. Aminated hollow mesoporous silica nanoparticles as an enhanced loading and sustained releasing carrier for doxorubicin delivery10.1016/j.micromeso.2020.110543 ↗
45. Ultrasmall antioxidant cerium oxide nanoparticles for regulation of acute inflammation10.1021/acsami.1c16126 ↗
46. Transient and long-lasting openings of the mitochondrial permeability transition pore can be monitored directly in intact cells by changes in mitochondrial calcein fluorescence10.1016/S0006-3495(99)77239-5 ↗
47. A simple practice guide for dose conversion between animals and human10.4103/0976-0105.177703 ↗
48. Souza · 2019 · 303
49. Physical principles of nanoparticle cellular endocytosis10.1021/acsnano.5b03184 ↗
50. The origin of heterogeneous nanoparticle uptake by cells10.1038/s41467-019-10112-4 ↗
51. Mitochondrial membrane potential and aging10.1111/j.1474-9728.2003.00079.x ↗
52. A moderate but not total decrease of mitochondrial membrane potential triggers apoptosis in neuron-like cells10.1097/00001756-200009110-00024 ↗
53. Adverse effects of butyl benzyl phthalate on the reproductive and hematopoietic systems of male rats10.1016/0300-483X(85)90015-0 ↗
54. Insight into the health risk implicated in mitochondrial toxicity of dibutyl phthalate exposure on zebrafish (Danio rerio) cells
55. Dibutyl phthalate affects insulin synthesis and secretion by regulating the mitochondrial apoptotic pathway and oxidative stress in rat insulinoma cells
56. Prepubertal Di-n-Butyl phthalate exposure alters sertoli and Leydig cell function and lowers bone density in adult Male mice10.1210/en.2015-1936 ↗
57. Effects of glucocorticoid-induced osteoporosis on bone tissue of rats with experimental periodontitis10.1016/j.archoralbio.2017.01.014 ↗
58. The apoptosis paradox in cancer10.3390/ijms23031328 ↗
59. DNA damage induces p53-independent apoptosis through ribosome stalling10.1126/science.adh7950 ↗
60. Therapeutic targeting of DNA damage response in cancer10.3390/ijms23031701 ↗
61. Fluorescent indicators for imaging nitric oxide production10.1002/(SICI)1521-3773(19991102)38:21<3209::AID-ANIE3209>3.0.CO;2-6 ↗
62. Immunogenic cell death in cancer therapy: present and emerging inducers10.1111/jcmm.14356 ↗
63. Mitochondrial permeability transition pore-dependent necrosis10.1016/j.yjmcc.2022.11.003 ↗
64. Nitrates and osteoporosis: which relationship?10.1016/j.ejim.2017.06.006 ↗
65. Bioactive silica nanoparticles promote osteoblast differentiation through stimulation of autophagy and direct association with LC3 and p6210.1021/nn5009879 ↗
66. Regulation of bone development and extracellular matrix protein genes by RUNX210.1007/s00441-009-0832-8 ↗
67. CTR9 drives osteochondral lineage differentiation of human mesenchymal stem cells via epigenetic regulation of BMP-2 signaling10.1126/sciadv.adc9222 ↗